Date of Publication: 05-Feb-2026
INTELLIGENCE OVERVIEW
Agency: US FDA
The U.S. FDA has updated the safety labeling for Capecitabine to strengthen warnings related to Dihydropyrimidine Dehydrogenase (DPD) deficiency. The update highlights the increased risk of severe or fatal toxicity in patients with partial or complete DPD deficiency and emphasizes the need for careful patient assessment.
INDUSTRY IMPACT
This update reinforces the growing regulatory focus on pharmacogenomics and patient-specific risk management. For manufacturers and MAHs, it underscores the importance of label lifecycle management, safety surveillance, and alignment with evolving FDA expectations. Clinicians and sponsors may also see increased emphasis on pre-treatment evaluation and risk communication.
KEYWORDS: Pharmacogenomics, Labeling Changes, Risk Management
REFERENCE: https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine